TMPRSS2 and prostate cancer: Through the immunohistochemical analysis of autopsy specimens, we demonstrate a significant reduction in pulmonary TMPRSS2 expression in ADT-treated patients compared to untreated prostate cancer patients and controls, with direct AR antagonists showing particularly potent suppressive effects.